Pathophysiology
Primary CBD stones form de novo in stasis (biliary strictures, parasitic infection); secondary stones migrate from the gallbladder. Obstruction raises intraductal pressure -> bacterial translocation from gut flora (E. coli, Klebsiella, Enterococcus) -> cholangitis.
Sources: ASGE Choledocholithiasis Guideline (Gastrointest Endosc 2019;89:1075); Tokyo Guidelines 2018 (J Hepatobiliary Pancreat Sci 2018;25:41); ACG Acute Cholangitis Overview (Am J Gastroenterol 2021 clinical update)
Clinical presentation
Right-upper-quadrant pain, obstructive jaundice (dark urine, pale stool, pruritus), Charcot triad (RUQ pain, jaundice, fever) for acute cholangitis; Reynolds pentad adds hypotension and altered mental status. Pancreatitis may coexist.
Diagnosis
LFTs: elevated ALP, GGT, direct bilirubin. Transabdominal US: dilated CBD >6 mm (>10 mm post-cholecystectomy). MRCP or EUS confirm stones with high sensitivity. High-probability criteria (CBD stone on US, bilirubin >4, CBD >6 mm + bilirubin 1.8-4): proceed directly to ERCP.
Management
ERCP with sphincterotomy and stone extraction (basket/balloon) is first-line; combined with laparoscopic cholecystectomy during the same admission for gallstone pancreatitis or symptomatic cholelithiasis. Acute cholangitis: Tokyo grading, broad-spectrum antibiotics (piperacillin-tazobactam), and biliary drainage within 24 h for moderate/severe grades.
Complications
Ascending cholangitis, gallstone pancreatitis, secondary biliary cirrhosis (chronic), post-ERCP pancreatitis (indomethacin PR reduces risk in high-risk patients).







